Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

D. Medical Industries Ltd. (DMED) Moves to Obtain CE Mark Approval for its Revolutionary Spring Zone Insulin Pump

|Includes: D. Medical Industries Ltd. (DMEDF)
D. Medical Industries, via its subsidiaries, is a constant innovator in cutting-edge medical devices sector for the delivery of diabetes treatments and other drugs. Today the Company announced submission of an application for CE Mark approval through its wholly owned Spring Health Solution Ltd subsidiary for the Spring™ Zone Insulin Delivery System.
The Spring Zone is a full replacement for generation one of the Company’s Spring ADI insulin pump and incorporates the proprietary Intellispring™ technology, resulting in vastly superior performance advantages in blockage, detachment direction, continuous insulin delivery checking and pressure/temp-related environmental adaptability. Also utilized in the product is the Company’s Total Line Control™ safety check system, resulting in full failsafe operability and offering what is arguably the safest and easiest means for reliably dispensing continuous, controlled and easily monitored insulin delivery.
COO at DMED, Hezkiah Tsoory, commented on the move for CE mark approval, explaining that, in addition to the EU’s 27 member nations, receipt of the CE mark will pave the way for market registrations in other regulated countries. Tsoory noted that among such countries are the Company’s five initial target markets for its pump products, namely Mexico and the BRIC nations.
The Spring Zone is the smallest, most lightweight insulin pump on the market today and offers an exceptionally quiet operational functionality, making it clearly superior to existing competition.
CCO for DMED, Zoe Myers, called the Spring Zone a hallmark of a new generation of diabetes support devices and explained that the elimination of the traditional motor and gear train in such pumps makes the Spring Zone more robust overall, with durability far exceeding anything else on the market.
The Company is also hard at work developing a single system which incorporates a continuous glucose monitoring system and an insulin pump.
Please see disclaimer on the MissionIR website